Literature DB >> 20035021

Safety of triazole antifungal drugs in patients with cancer.

Simon Cronin1, Pranatharthi H Chandrasekar.   

Abstract

Triazole drugs are widely used in cancer patients for prophylaxis and treatment of life-threatening invasive fungal infections. Fluconazole, available for over two decades, is safe and effective in patients with cancer; however, the excellent safety profile of fluconazole may not be applicable to the newer triazoles. Itraconazole, voriconazole and posaconazole are associated with adverse events, and drug interactions frequently occur, particularly in cancer patients, since the triazoles and many drugs used in cancer chemotherapy are metabolized via a common metabolic pathway, the hepatic cytochrome P450 system. Close monitoring for drug interactions is needed when triazoles are used with anti-neoplastic drugs and dosage modification of the triazole or its discontinuation may be required. Monitoring of triazole serum concentrations is becoming an important aspect of management to minimize toxicity and ensure efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035021     DOI: 10.1093/jac/dkp464

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

Review 1.  Azole interactions with multidrug therapy in pediatric oncology.

Authors:  Antonio Ruggiero; Roberta Arena; Andrea Battista; Daniela Rizzo; Giorgio Attinà; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

2.  Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

Authors:  Michelle R Ananda-Rajah; Andrew Grigg; Maria T Downey; Ashish Bajel; Tim Spelman; Allen Cheng; Karin T Thursky; Janette Vincent; Monica A Slavin
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  Silica-Supported Oligomeric Benzyl Phosphate (Si-OBP) and Triazole Phosphate (Si-OTP) Alkylating Reagents.

Authors:  Pradip K Maity; Saqib Faisal; Alan Rolfe; Diana Stoianova; Paul R Hanson
Journal:  J Org Chem       Date:  2015-10-02       Impact factor: 4.354

4.  The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.

Authors:  Ann R Holmes; Mikhail V Keniya; Irena Ivnitski-Steele; Brian C Monk; Erwin Lamping; Larry A Sklar; Richard D Cannon
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

5.  Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.

Authors:  Anastasia Wasylyshyn; Kathleen A Linder; Caroline G Castillo; Shiwei Zhou; Carol A Kauffman; Marisa H Miceli
Journal:  Mycopathologia       Date:  2020-01-14       Impact factor: 2.574

6.  Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.

Authors:  Corrado Girmenia; Anna Maria Frustaci; Giuseppe Gentile; Clara Minotti; Claudio Cartoni; Saveria Capria; Silvia Maria Trisolini; Angela Matturro; Giuseppina Loglisci; Roberto Latagliata; Massimo Breccia; Giovanna Meloni; Giuliana Alimena; Robin Foà; Alessandra Micozzi
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

Review 7.  Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.

Authors:  Christopher C Dvorak; Brian T Fisher; Lillian Sung; William J Steinbach; Michael Nieder; Sarah Alexander; Theoklis E Zaoutis
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

8.  Associations between plasma hydroxylated metabolite of itraconazole and serum creatinine in patients with a hematopoietic or immune-related disorder.

Authors:  Yumi Imoto; Takafumi Naito; Yukari Miyadera; Takaaki Ono; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2020-10-08       Impact factor: 2.953

Review 9.  [Candida infections in the elderly].

Authors:  H Hof; G Mikus
Journal:  Z Gerontol Geriatr       Date:  2013-01       Impact factor: 1.281

10.  The 1,2,3-triazole derivative KP-A021 suppresses osteoclast differentiation and function by inhibiting RANKL-mediated MEK-ERK signaling pathway.

Authors:  Hye Jung Ihn; Doohyun Lee; Taeho Lee; Hong-In Shin; Yong Chul Bae; Sang-Hyun Kim; Eui Kyun Park
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.